BRCA MUTATION TESTING: ETHICAL AND COUNSELING PERSPECTIVES ON GYNECOLOGIC AND BREAST CANCER RISK

R Hansli, MD Vijaya Rani, Anitha, Dr. Harsimranjit Kaur, Dr. Gaurav Bajaj, Kiran Haridas

Research Scholar, Sikkim Professional University, India, ramavathhansli@gmail.com
Research Scholar, Sikkim Professional University, India, vijayadaniel2020@gmail.com
Research Scholar, Sikkim Professional University, India, ragiranitha@gmail.com
Medical Officer, General Emergency, Geebee Hospital, India, simranjit648@gmail.com
MD, MPH, Department Healthcare & Medical Science, Annamalai University, Tamil Nadu, India, gaurav_54bajaj@yahoo.com
Clinical pharmacologist, Bangalore, drkiranharidas@gmail.com

Abstract

In order to identify individuals who are at a higher risk for gynecologic and breast malignancies, BRCA mutation testing is essential. The risk of breast cancer and other cancers is greatly increased by harmful mutations in the BRCA1 and BRCA2 genes.

Methods

This study was directed to examine the impact of BRCA mutations on cancer risk, the effectiveness of genetic counseling, and the role of molecular genetic testing in identifying pathogenic variants. Data synthesis involved analyzing studies reporting cancer risks associated with BRCA mutations, genetic testing methodologies, and recommended surveillance and risk management strategies.

Results

BRCA1- and BRCA2-associated hereditary breast cancer are characterized by an increased risk of various cancers, with estimates varying depending on gender and mutation type. Women with BRCA mutations have higher incidences of breast while men with BRCA2 mutations are more susceptible to breast cancers. Molecular genetic testing, particularly sequence analysis, is effective in detecting pathogenic variants, although gene-targeted deletion/duplication analysis has lower sensitivity. Surveillance and risk-reducing strategies, such as enhanced screening and prophylactic surgeries, are recommended for BRCA variant carriers to mitigate cancer risks.

Conclusion

BRCA mutation testing in identifying high-risk individuals for breast cancers, emphasizing the necessity of genetic counseling and personalized risk management for informed decision-making and improved patient outcomes. Ethical considerations highlight the importance of informed consent and ethical concerns, emphasizing the need for a holistic approach to optimize cancer care.

Keywords: BRCA mutation testing, genetic counseling, molecular genetic testing, surveillance, risk reduction strategies, ethical considerations.

Introduction

BRCA mutation testing is essential for identifying and treating those who are more susceptible to breast and gynecologic cancers [1]. The identification of deleterious variations in the BRCA1 and BRCA2 genes has transformed our knowledge of the genetic propensity to cancer, providing avenues for customized risk evaluation and focused therapies [2]. However, the ethical implications and counseling considerations surrounding BRCA mutation testing are complex and multifaceted. By examining the literature, this research aims to shed light on the ethical considerations inherent in genetic testing, the role of genetic counseling in informed decision-making, and the implications of test results for individuals and their families.

Through an analysis of secondary source literature, this study seeks to elucidate key themes and recommendations related to BRCA mutation testing, including the importance of genetic counseling, the utilization of comprehensive testing methodologies, and the implementation of personalized surveillance and risk reduction strategies. By synthesizing existing knowledge in this field, this study contributes to a deeper understanding of the ethical and counseling dimensions of BRCA mutation testing and its implications for cancer risk management [3].In the subsequent sections, we delve into the ethical considerations surrounding BRCA mutation testing, explore the role of genetic counseling in facilitating informed decision-making, and discuss the implications of test results for individuals and their families. This study intends to offer insights into the ethical and counseling views on gynecologic and breast cancer risk related with BRCA mutation testing by a thorough assessment of these subjects.

Methodology

Study Design: This study utilizes a qualitative research design based on the synthesis of existing literature on BRCA mutation testing and cancer risk management. The research methodology

involves the analysis of secondary source data to examine "key themes, trends, and recommendations" related to BRCA mutations and
cancer risk management strategies. Peer-reviewed research articles, clinical guidelines, and expert recommendations from reputable sources were reviewed to inform the study design and methodology. This study aims to evaluate the efficacy of BRCA mutation testing in identifying individuals at high risk for gynecologic and breast cancers and to assess the effectiveness of cancer risk management strategies in this population.
Data Collection: Data were collected from secondary sources, including research articles, review papers, clinical guidelines, and expert recommendations. Relevant information on BRCA mutation testing, cancer risks associated with BRCA1 and BRCA2 mutations, and recommended surveillance and risk reduction strategies were extracted and synthesized for analysis.
Data Analysis: The collected data were analyzed thematically to identify patterns, common themes, and variations in the literature regarding BRCA mutation testing and cancer risk management. Key findings were summarized, and important insights were extracted to address the research objectives.

Results & Discussion

BRCA Mutation Testing and Cancer Risk Management

The results of the literature review highlight how important BRCA mutation testing is for determining who is more likely to develop breast or gynecologic cancers. The risk of several malignancies, including pancreatic, ovarian, prostate, and breast cancers, is markedly increased by harmful mutations in the BRCA1 and BRCA2 genes. Additionally, certain BRCA mutations are associated with subtypes of Fanconi anemia, further increasing cancer susceptibility [4].
An increased risk of both male and female "breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and, to a lesser extent, other cancers like prostate, pancreatic, and melanoma, characterizes BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC)", particularly in those with a BRCA2 pathogenic variant. The context in which cancer risk estimates are derived greatly influences such estimates.
Other study by (Bedrick et al.,2021) [5] highlight the varied impact of BRCA mutations. For instance, women with BRCA mutations have a higher incidence of breast and ovarian cancers, while men with BRCA2 mutations are more susceptible to breast and prostate cancers. Both genders also have a marginally increased risk of pancreatic cancer.
Similarly study by (Bertozzi et al.,2023) [6] suggested, BRCA mutation testing remains a pivotal tool for identifying individuals at high risk for several types of cancer, thereby aiding in personalized risk management and prevention strategies. Table 2 provides a detailed summary of malignancy risks for individuals with germline BRCA1 or BRCA2 pathogenic variants.

Genetic Counseling and Testing

The finding highlights the importance of genetic counseling in facilitating informed decision-making regarding BRCA mutation testing. Recommendations from organizations such as the "U.S. Preventive Services Task Force" and the "National Comprehensive Cancer Network" emphasize the need for personalized risk assessment and genetic counseling for individuals with relevant family histories or specific cancer diagnoses.

Table 1: "Molecular Genetic Testing Used in BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer (HBOC)"

Gene	Proportion of BRCA1 & BRCA2 Associated HBOC Attributed to Pathogenic Variants in Gene	Proportion of Pathogenic Variants Detected by Method
BRCA1	66%	87%-89% (Sequence analysis), 11%-13% (Gene- targeted deletion/ duplication analysis)
BRCA2	34%	97%-98% (Sequence analysis), 2%-3% (Gene-targeted deletion/ duplication analysis)

The distribution of harmful variations in the BRCA1 and BRCA2 genes in people with inherited breast and ovarian cancer (HBOC) is shown in the table, along with the efficiency of different genetic testing methods in detecting these variants. Approximately 66% of HBOC cases are attributed to pathogenic variants in the BRCA1 gene, while the remaining 34% are associated with BRCA2 variants. This distribution underscores the significance of both genes in hereditary cancer predisposition. Hence study finding indicates that sequence analysis is highly effective in detecting pathogenic variants in both BRCA1 and BRCA2 genes, capturing approximately 87%-89% of variants in BRCA1 and 97%-98% in BRCA2. On the other hand, gene-targeted deletion/duplication analysis is less sensitive, identifying only 11%-13% of BRCA1 variants and 2%-3% of BRCA2 variants.
In another study by (Clarfield et al.,2022) [9] findings align with current research highlighting the predominance of BRCA1 and BRCA2 mutations in HBOC cases. Additionally, the high detection rates of sequence analysis corroborate its widespread use as the primary method for identifying pathogenic variants. However, the relatively lower sensitivity of gene-targeted deletion/duplication analysis underscores the importance of employing complementary testing approaches to ensure comprehensive mutation detection.
Overall, the data presented in the table underscore the importance of molecular genetic testing in identifying pathogenic variants associated with HBOC and emphasize the need for robust testing methodologies to accurately capture genetic mutations in BRCA1 and BRCA2 genes.
Testing, typically done via blood or saliva samples, confirms BRCA mutations. For cancer patients discovering mutations through tumor testing, germline genetic tests confirm inheritance. Testing affected relatives first can clarify genetic risk for others. BRCA1 and BRCA2 mutations increase cancer risk, especially for breast and ovarian cancers. Other studies by (Gasparri et al.,2022) [11] echo the importance of personalized risk assessment and proper genetic counseling to guide testing decisions. The importance of genetic counseling and personalized risk assessment in guiding decisions related to

BRCA gene testing is well-supported by various studies and guidelines.

Studies (Lugo et al.,2020) [10] have shown that genetic counseling significantly improves patients' understanding of genetic testing, their perceived risk of cancer, and their decision-making process regarding testing. It helps individuals weigh the potential benefits and drawbacks of testing, ensuring they make informed choices aligned with their values and preferences.

Molecular Genetic Testing

The synthesis of literature data reveals the distribution of pathogenic variants in BRCA1 and BRCA2 genes among individuals with HBOC. Sequence analysis emerges as the primary method for detecting pathogenic variants, with high detection rates observed for both BRCA1 and BRCA2 mutations. However, gene-targeted deletion/duplication analysis demonstrates lower sensitivity, highlighting the importance of comprehensive testing approaches.

Table 2: "Risk of Malignancy in Individuals with a Germline BRCA1 or BRCA2 Pathogenic Variant"

Cancer Type	General Population Risk	Risk for Malignancy (BRCA1)	Risk for Malignancy (BRAC2)
Breast	12%	55%-72% by age 70	45%-69% by age 70
Contralateral breast cancer	2% w/in 5 yrs	20%-30%w/in 10 yrs; 40%-50% w/in 20 yrs	20%-30%w/in 10 yrs; 40%-50% w/in 20 yrs
Ovarian	1%-2%	39%-44%	11%-17%
Male breast	0.1%	1%-2%	6%-8%
Prostate	6% by age 69 yrs	21% by age 75 yrs; 29% by age 85 yrs	27% by age 75 yrs; 60% by age 85 yrs
Pancreatic	0.5%	1%-3%	3%-5% by age 70 yrs
Melanoma (cutaneous & ocular)	1.6%	Elevated risk	Elevated risk

The table presents the comparative risks of malignancies in individuals with germline BRCA1 or BRCA2 pathogenic variants compared to the general population. It highlights significantly elevated risks for "breast, ovarian, male breast, prostate, pancreatic, and melanoma cancers" associated with these mutations.

The findings in Table 2 align with numerous studies indicating the substantially increased risks of various cancers in individuals with BRCA1 or BRCA2 pathogenic variants compared to the general population. For breast cancer, studies have consistently shown a much higher lifetime risk, particularly by age 70, emphasizing the importance of early screening and risk-reducing strategies in BRCA mutation carriers.

Comparetto et al.'s 2019 study [7] also found that ovarian cancer risks are higher, highlighting the necessity of proactive surveillance and risk-reduction measures for those who are impacted. The significance of taking these diseases into account in the therapy and surveillance of BRCA mutation carriers is further highlighted by the higher risks of pancreatic, prostate, and male breast cancer. Overall, the table offers a thorough summary of the elevated cancer risks linked to pathogenic mutations in BRCA1 and BRCA2, emphasizing the significance of individualized screening, surveillance, and risk-reduction measures in impacted individuals. Additionally, fallopian tube, primary peritoneal, pancreatic, and prostate cancers are all made more likely by BRCA mutations. Breast cancer risk is increased in men with BRCA2 mutations and in certain cases with BRCA1 mutations. Fanconi anemia subtypes associated with pediatric malignancies and leukemia are caused by specific BRCA mutations.

Reducing Cancer Risk for BRCA1 and BRCA2 Variant Carriers

Enhanced screening for women with BRCA mutations may involve initiating breast cancer screening earlier, increasing the frequency of screenings, and incorporating MRI alongside mammography. While no effective ovarian cancer screening exists, some individuals utilize transvaginal ultrasound and CA-125 blood tests. Men with BRCA mutations might consider annual breast exams starting at age 35 and PSA testing for prostate cancer beginning at age 40. Risk-reducing surgeries, such as "bilateral mastectomy" and "salpingo-oophorectomy", can significantly decrease the risks of breast and ovarian cancers, although these procedures do not completely eliminate the risks and carry potential complications, including bleeding, infection, psychological impacts, and early menopause [4]. Chemoprevention strategies include the use of drugs like tamoxifen and raloxifene, which may lower breast cancer risk, particularly in BRCA2 carriers. Additionally, oral contraceptives can reduce ovarian cancer risk by approximately 50%, though they may increase the risk of breast cancer and have other side effects. Genetic testing for BRCA1 and BRCA2 variants remains a cornerstone of identifying individuals at enlarged risk and guiding personalized management strategies [8].

Table 3: "Recommended Surveillance for Women with BRCA1- and BRCA2-Associated Hereditary Breast Cancer"

System/ Concern	Evaluation	Frequency
Breast cancer	Breast self-exam	Monthly
	Clinical breast exam	Every 6 -12 mos beginning at age 25 yrs
	Mammogram	Annually beginning at age 30 yrs
	Breast MRI	Annually beginning at age 25 yrs or earlier if breast cancer was diagnosed in family member <age 30 yrs

The suggested surveillance plan for women with hereditary breast cancers associated with BRCA1 or BRCA2 is shown in this table. It consists of annual mammograms starting at age 30, yearly breast self-examinations, clinical breast exams every six to twelve months starting at age 25, and annual breast MRIs starting at age 25 or earlier if a family member under 30 has been diagnosed with breast cancer. Several studies have demonstrated the benefits of regular breast self-exams, clinical breast exams, mammograms, and breast MRI in detecting breast cancer at early stages in BRCA mutation carriers. Early detection allows for timely intervention, potentially improving survival rates and reducing the need for aggressive treatments. It's important to note that while surveillance protocols are essential, they may vary based on individual risk factors, genetic mutation type, and personal preferences. Therefore, personalized discussions between patients and healthcare providers are crucial to tailor surveillance plans to each individual's needs and circumstances.

Ethical Perspective

Genetic counseling is essential for BRCA1 and BRCA2 testing to ensure informed consent. Informed consent means individuals make fully informed, autonomous decisions about genetic testing without coercion, reflecting their values. Pretest counseling should cover the pros and cons of testing, including genetics of hereditary cancers, associated risks, technical limitations, result timelines, and risk management options. It should also address psychosocial and ethical issues like psychological distress, impact on family, and potential discrimination [11].

Overall discussion underscores the significance of BRCA mutation testing in identifying individuals at heightened risk for multiple cancers, enabling tailored risk management strategies. Genetic counseling emerges as a vital component, ensuring informed decision-making associated with testing. Overall, integrating BRCA mutation testing with comprehensive counseling and risk management approaches is crucial for optimizing outcomes in those facing increased cancer susceptibility.

Conclusion

In conclusion, the study highlights the crucial role of BRCA mutation testing in identifying individuals at elevated risk for various cancers, particularly breast cancers. Genetic counseling is emphasized as essential for informed decision-making and addressing potential psychological impacts associated with testing. Integrating BRCA mutation testing with comprehensive counseling and personalized risk management strategies is paramount for improving outcomes in individuals with increased cancer susceptibility. Ethical considerations underscore the importance of ensuring informed consent and addressing psychosocial and ethical issues related to testing. Overall, the study emphasizes the need for a holistic approach to BRCA mutation testing and cancer risk management to optimize patient care and outcomes.

References

1. Nelson, H.D., Pappas, M., Cantor, A., , 2019. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. Jama, 322(7), pp.666-685.

2. Newman, L., 2019. US Preventive Services Task Force breast cancer recommendation statement on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. JAMA surgery, 154(10), pp.895-896.

3. Liang, M.I., Wong, D.H., Walsh, C.S., 2018. Cancer genetic counseling and testing: perspectives of epithelial ovarian cancer patients and gynecologic oncology healthcare providers. Journal of Genetic Counseling, 27(1), pp.177-186.

4. Neves, N.M.B.C., Boaventura, C.S., Costa, M.A.F., 2022. Ethical implications of genetic testing of susceptibility to breast cancer. Revista Bioética, 30, pp.636-643.

5. Bedrick, B.S., Fruhauf, T.F., Martin, S.J., 2021. Creating breast and gynecologic cancer guidelines for transgender patients with BRCA mutations. Obstetrics & Gynecology, 138(6), pp.911-917.

6. Bertozzi S, Londero AP, Xholli A, Azioni G,. Risk-reducing breast and gynecological surgery for BRCA mutation carriers: a narrative review. Journal of Clinical Medicine. 2023 Feb 10;12(4):1422.

7. Comparetto, C. and Borruto, F., 2019. The Role of Genetic Counseling in Gynecological Oncology. OBM Genetics, 3(4), pp.1-45.

8. Bertozzi S, Londero AP, Xholli A, Azioni G, Di Vora R. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers": A Narrative Review. J Clin Med. 2023 Feb 10;12(4):1422. doi: 10.3390/jcm12041422. PMID: 36835955; PMCID: PMC9967164.

9. Clarfield L., Diamond L., Jacobson M. Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2. Curr. Oncol. 2022;29:2132–2140. doi: 10.3390/curroncol29030172.

10. Lugo Santiago N., Smith E., Cox M., Wan C.S.,. Ovarian Cancer After Prophylactic Salpingectomy in a Patient with Germline BRCA1 Mutation. Obstet. Gynecol. 2020;135:1270–1274.

11. Gasparri M.L., Bellaminutti S., Farooqi A.A., Endometrial Cancer and BRCA Mutations: A Systematic Review. J. Clin. Med. 2022;11:3114